Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Pharmaceutical
UK-based company NeRRe Therapeutics, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, has announced the appointment of Ian Nicholson as Chief Business Officer (CBO). 19 March 2014
article
Spherix Incorporated (NASDAQ: SPEX) have announced that Frank Reiner has joined the company as vice president of
licensing, where he will report to chief executive Anthony Hayes and play a key role in the company's licensing efforts. 19 March 2014
Biotechnology
Celgene UK and Ireland have announced the appointment of Rob Moore as the new Inflammation and Immunology (I&I) Business Unit Director. 19 March 2014
Biotechnology
In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline and intentions to take multiple proprietary ADCs into clinical development. 19 March 2014
Biotechnology
The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product, FT011, an antifibrotic to prevent the tissue fibrosis associated with diabetic nephropathy. 18 March 2014
Pharmaceutical
Avion Pharmaceuticals, a US-based specialty pharmaceutical company, has announced the promotion of Mike Sullivan to the position of president. 18 March 2014
Pharmaceutical
Germany-based Formycon has appointed Bernhard Hampl, a top pharmaceuticals manager from the USA, to its advisory board. 18 March 2014
Pharmaceutical
The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini spoke about pharma innovation in action at The Economist’s Pharma Summit in London on Thursday. 17 March 2014
Pharmaceutical
Health care is a human right and the pharma industry must evolve to meet future challenges, claims Elias Zerhouni, president of Global R&D at French drug major Sanofi. 14 March 2014
Pharmaceutical
The way pharma works needs to change with an increasing focus on collaborations, sharing data and access to medicines, according to a panel discussion at The Economist’s Pharma Summit in London yesterday. 14 March 2014
Biotechnology
Australian product development company Clinical Network Services (CNS) has launched a new UK office headed by Paul Cronin who joins as UK Director and Director, Business Development. 10 March 2014
Pharmaceutical
US headquartered Moderna Therapeutics, a leader in the development of RNA (mRNA) Therapeutics has announced that Lorence Kim will join Moderna's executive leadership team as chief financial officer, effective April 21. 7 March 2014
Pharmaceutical
Aquavit Pharmaceuticals, a private US-based life science company, has announced the appointment of David Goldberg as chief medical officer. 6 March 2014
Biotechnology
French biopharmaceutical company Genticel has recruited Sophie Olivier as chief medical officer to lead the clinical development of its pipeline, in particular the ProCervix Phase II trial. 4 March 2014
Biotechnology
Australian biotech company Novogen has announced the appointments of new board members and a strategic advisor to support its transition into a clinical-stage company with a growing US presence and an investor base in the USA and Australia. 4 March 2014
Biotechnology
Executives are moving back to an ‘ex-directory’ world, where smaller, restricted networks are of the highest value, according to RSA, a global life sciences executive search and interim management specialist. 3 March 2014
Biotechnology
Australian biotechnology firm Phosphagenics has appointed biotech industry veterans Lawrence Gozlan, Nathan Drona and Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis. 3 March 2014
Pharmaceutical
Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch Doliveux, saying that Jean-Christophe Tellier, currently executive vice president, Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee as of March 1, 2014. 21 February 2014
Biosimilars
Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding Thierry Hulot, who created the biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of last year. 20 February 2014
Pharmaceutical
UK-based drug development company Avillion LLP has appointed Allison Jeynes-Ellis as chief executive. 18 February 2014
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze